Opaleye Management Inc. Purchases 50,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) Stock

Harrow Health, Inc. (NASDAQ:HROW) major shareholder Opaleye Management Inc. bought 50,000 shares of Harrow Health stock in a transaction dated Thursday, March 28th. The stock was acquired at an average cost of $12.82 per share, with a total value of $641,000.00. Following the transaction, the insider now owns 3,745,600 shares of the company’s stock, valued at approximately $48,018,592. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Wednesday, March 20th, Opaleye Management Inc. bought 50,600 shares of Harrow Health stock. The stock was acquired at an average cost of $9.65 per share, with a total value of $488,290.00.

Harrow Health Stock Up 3.9 %

NASDAQ HROW traded up $0.50 on Thursday, reaching $13.23. The company had a trading volume of 837,654 shares, compared to its average volume of 452,178. Harrow Health, Inc. has a 52-week low of $7.60 and a 52-week high of $28.25. The stock has a market capitalization of $467.81 million, a P/E ratio of -17.65 and a beta of 0.45. The company’s fifty day moving average is $10.66 and its 200 day moving average is $11.59. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60.

Analyst Upgrades and Downgrades

HROW has been the subject of a number of analyst reports. TheStreet downgraded Harrow Health from a “c-” rating to a “d+” rating in a research note on Tuesday, December 12th. B. Riley lowered their price objective on Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HROW. Braidwell LP bought a new position in shares of Harrow Health during the 1st quarter worth $30,736,000. BlackRock Inc. boosted its stake in Harrow Health by 261.1% in the 2nd quarter. BlackRock Inc. now owns 1,789,382 shares of the company’s stock worth $34,070,000 after purchasing an additional 1,293,806 shares during the period. Private Capital Management LLC bought a new stake in shares of Harrow Health during the 2nd quarter valued at about $7,253,000. State Street Corp boosted its position in shares of Harrow Health by 495.7% during the 2nd quarter. State Street Corp now owns 583,873 shares of the company’s stock valued at $11,117,000 after acquiring an additional 485,860 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY bought a new stake in shares of Harrow Health during the 3rd quarter valued at about $5,655,000. Institutional investors own 72.76% of the company’s stock.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.